Gastrinoma
Gastrinomas are neuroendocrine tumors (NETs), usually located in the duodenum or pancreas, that secrete gastrin and cause a clinical syndrome known as Zollinger–Ellison syndrome (ZES).
≈ 3 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Gastrinomas are neuroendocrine tumors (NETs), usually located in the duodenum or pancreas, that secrete gastrin and cause a clinical syndrome known as Zollinger–Ellison syndrome (ZES). A large number of gastrinomas develop in the pancreas or duodenum, with near-equal frequency, and approximately 10% arise as primary neoplasms in lymph nodes of the pancreaticoduodenal region (gastrinoma triangle).
Most gastrinomas are sporadic (75–80%), whereas approximately 20–25% are associated with multiple endocrine neoplasia type 1 (MEN-1). Over 50% of gastrinomas are malignant and can metastasize to regional lymph nodes and liver. One fourth of gastrinomas are related to multiple endocrine neoplasia type 1, Zollinger–Ellison syndrome, peptic ulcer disease.
Signs and symptoms
Gastrinoma in the early stages will have signs and symptoms of indigestion or similar to irritable bowel disease (IBD) such as: Hypergastrinemia Refractory or recurrent peptic ulcers involving duodenum Chronic diarrhea Generalized cancer symptoms Abdominal pain Gastrointestinal bleeding Obstruction of intestine Weight loss /poor appetite Anemia (Due to vitamin B 12 malabsorption, and bleeding) Hematemesis Gastroesophageal reflux disease Esophageal complications (Barrett's esophagus, esophagitis, stricture formation) Vomiting Steatorrhea
Diagnosis
In many cases, gastrinoma is diagnosed based on the patient's history which is typically characterized by recurrent episodes of peptic ulcer disease or by severe reflux esophagitis and/or diarrhea or by acid-related symptoms which fail to respond to standard treatment regimens. To confirm the diagnosis of gastrinoma a series of blood tests must be made.
One of those tests is the serum gastrin level, which is the most reliable test for patients with gastrinoma. The normal levels of gastrin are 150 pg/mL ( > 72.15 pmol/L); therefore elevated levels of > 1000 pg/mL (> 480 pmol/L) would establish the diagnosis of gastrinoma.
Another test that can be conducted is the secretin stimulated test, which is useful in patients who have the sign and symptoms of gastrinoma but the gastrin levels are below 3 ) that would neutralize the acidic environment due to high gastrin levels. Therefore, if the patient's level of gastrin remains consistently high indicating gastrin release due to tumor such as gastrinoma.
Other commonly used tests to further confirm the diagnosis are CT scan of the abdominal area Somatostatin receptor scintigraphy which is used to identify the location of the tumor PET scan Endoscopic ultrasound if there are no signs of tumor metastases.
Treatment
Surgery is first line treatment in gastrinomas; however it often fails to be curative. Proton-pump inhibitors such as omeprazole. This group of medications suppress the acid secretion.
H 2 -receptor antagonist similarly decrease acid secretion. Octreotide injections directly release somatostatin hormone that inhibits gastrin release. Chemotherapy.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1350149796 under CC BY-SA 4.0; modifications have been made.